FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029053119> ?p ?o ?g. }

• W3029053119 endingPage "4501" @default.
• W3029053119 startingPage "4501" @default.
• W3029053119 abstract "4501 Background: Periop. FLOT has become SOC for resectable, esophagogastric adenocarcinoma. However, patient’s outcome is still poor. This trial evaluates the addition of the VEGF-R2 inhibitor ramucirumab (RAM) to FLOT for resectable patients (pts). Methods: This is a prospective, international, randomized, investigator-initiated phase II/III trial. Pts with resectable, Her2-negative, adenocarcinoma of the stomach and GEJ (≥ cT2 or cN+) were enrolled. Pts were randomized to 4 pre-and post-operative cycles of FLOT (docetaxel 50 mg/m²; oxaliplatin 85 mg/m²; leucovorin 200 mg/m²; 5-FU 2600 mg/m², q2w) alone (Arm A) or the same regimen with RAM 8mg/kg q2w, followed by 16 cycles RAM (Arm B, FLOT-RAM). Important endpoints of phase II (exploratory) were major pathological (complete and nearly complete) response, centrally assessed acc. to Becker criteria, R0-resection rate, and safety. GEJ type I tumors and pts requiring trans-thoracic esophagectomy were excluded for safety reasons during the conduct of the study. Results: In total, 180 pts were randomized. Baseline characteristics were similar between arms (male, 73%; median age, 60y; cT3/T4, 83%; cN+, 78%; GEJ, 54%; signet-ring cells, 40%). However, the FLOT-RAM arm included more unfavorable pts with T4 (9% vs. 4%), Siewert type I tumors (18% vs. 13%), impaired ECOG PS of 1 (34% vs. 20%), and concomitant disease (87% vs. 79%). 91% of pts with FLOT and 92% with FLOT-RAM completed the 4 pre- cycles. R0-resection (in the full set) could be achieved in 83% of pts with FLOT and 97% of pts with FLOT-RAM (p = 0.0049). The rate of major path response was similar in both arms and was 30% for FLOT and 27% for FLOT-RAM. Surgical morbidity was observed in 37% of pts with FLOT and 44% of pts with FLOT-RAM. Mortality was 2.5% with FLOT and 5.9% with FLOT-RAM including GEJ type I tumors and dropped to 2.9% in both arms after excluding type I tumors per amendment. There was bit more G≥3 adverse events with FLOT-RAM (78% vs. 89%). Conclusions: In this phase II trial, the addition of ramucirumab to perioperative FLOT significantly improved R0-resection rates without an impact on path response, mainly because more patients could proceed to operation. The FLOT-RAM is safe, when type I tumors are excluded. Clinical trial information: NCT02661971 ." @default.
• W3029053119 created "2020-06-05" @default.
• W3029053119 creator A5001177562 @default.
• W3029053119 creator A5003615636 @default.
• W3029053119 creator A5005554580 @default.
• W3029053119 creator A5009130863 @default.
• W3029053119 creator A5012380788 @default.
• W3029053119 creator A5018436714 @default.
• W3029053119 creator A5023227183 @default.
• W3029053119 creator A5034232595 @default.
• W3029053119 creator A5034426711 @default.
• W3029053119 creator A5038723818 @default.
• W3029053119 creator A5040590864 @default.
• W3029053119 creator A5046559582 @default.
• W3029053119 creator A5061424072 @default.
• W3029053119 creator A5066426980 @default.
• W3029053119 creator A5067479478 @default.
• W3029053119 creator A5072163653 @default.
• W3029053119 creator A5073286593 @default.
• W3029053119 creator A5075191891 @default.
• W3029053119 creator A5076298207 @default.
• W3029053119 creator A5079511177 @default.
• W3029053119 date "2020-05-20" @default.
• W3029053119 modified "2023-10-18" @default.
• W3029053119 title "Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM." @default.
• W3029053119 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.4501" @default.
• W3029053119 hasPublicationYear "2020" @default.
• W3029053119 type Work @default.
• W3029053119 sameAs 3029053119 @default.
• W3029053119 citedByCount "20" @default.
• W3029053119 countsByYear W30290531192020 @default.
• W3029053119 countsByYear W30290531192021 @default.
• W3029053119 countsByYear W30290531192022 @default.
• W3029053119 countsByYear W30290531192023 @default.
• W3029053119 crossrefType "journal-article" @default.
• W3029053119 hasAuthorship W3029053119A5001177562 @default.
• W3029053119 hasAuthorship W3029053119A5003615636 @default.
• W3029053119 hasAuthorship W3029053119A5005554580 @default.
• W3029053119 hasAuthorship W3029053119A5009130863 @default.
• W3029053119 hasAuthorship W3029053119A5012380788 @default.
• W3029053119 hasAuthorship W3029053119A5018436714 @default.
• W3029053119 hasAuthorship W3029053119A5023227183 @default.
• W3029053119 hasAuthorship W3029053119A5034232595 @default.
• W3029053119 hasAuthorship W3029053119A5034426711 @default.
• W3029053119 hasAuthorship W3029053119A5038723818 @default.
• W3029053119 hasAuthorship W3029053119A5040590864 @default.
• W3029053119 hasAuthorship W3029053119A5046559582 @default.
• W3029053119 hasAuthorship W3029053119A5061424072 @default.
• W3029053119 hasAuthorship W3029053119A5066426980 @default.
• W3029053119 hasAuthorship W3029053119A5067479478 @default.
• W3029053119 hasAuthorship W3029053119A5072163653 @default.
• W3029053119 hasAuthorship W3029053119A5073286593 @default.
• W3029053119 hasAuthorship W3029053119A5075191891 @default.
• W3029053119 hasAuthorship W3029053119A5076298207 @default.
• W3029053119 hasAuthorship W3029053119A5079511177 @default.
• W3029053119 hasConcept C121608353 @default.
• W3029053119 hasConcept C126322002 @default.
• W3029053119 hasConcept C141071460 @default.
• W3029053119 hasConcept C2779384505 @default.
• W3029053119 hasConcept C2779551604 @default.
• W3029053119 hasConcept C2780962732 @default.
• W3029053119 hasConcept C2781182431 @default.
• W3029053119 hasConcept C2781413609 @default.
• W3029053119 hasConcept C31174226 @default.
• W3029053119 hasConcept C31760486 @default.
• W3029053119 hasConcept C526805850 @default.
• W3029053119 hasConcept C535046627 @default.
• W3029053119 hasConcept C71924100 @default.
• W3029053119 hasConcept C90924648 @default.
• W3029053119 hasConceptScore W3029053119C121608353 @default.
• W3029053119 hasConceptScore W3029053119C126322002 @default.
• W3029053119 hasConceptScore W3029053119C141071460 @default.
• W3029053119 hasConceptScore W3029053119C2779384505 @default.
• W3029053119 hasConceptScore W3029053119C2779551604 @default.
• W3029053119 hasConceptScore W3029053119C2780962732 @default.
• W3029053119 hasConceptScore W3029053119C2781182431 @default.
• W3029053119 hasConceptScore W3029053119C2781413609 @default.
• W3029053119 hasConceptScore W3029053119C31174226 @default.
• W3029053119 hasConceptScore W3029053119C31760486 @default.
• W3029053119 hasConceptScore W3029053119C526805850 @default.
• W3029053119 hasConceptScore W3029053119C535046627 @default.
• W3029053119 hasConceptScore W3029053119C71924100 @default.
• W3029053119 hasConceptScore W3029053119C90924648 @default.
• W3029053119 hasFunder F4320330904 @default.
• W3029053119 hasIssue "15_suppl" @default.
• W3029053119 hasLocation W30290531191 @default.
• W3029053119 hasOpenAccess W3029053119 @default.
• W3029053119 hasPrimaryLocation W30290531191 @default.
• W3029053119 hasRelatedWork W1973824708 @default.
• W3029053119 hasRelatedWork W2163079911 @default.
• W3029053119 hasRelatedWork W2518765238 @default.
• W3029053119 hasRelatedWork W2596788301 @default.
• W3029053119 hasRelatedWork W2767947279 @default.
• W3029053119 hasRelatedWork W2769319247 @default.
• W3029053119 hasRelatedWork W2959428144 @default.
• W3029053119 hasRelatedWork W3199274710 @default.
• W3029053119 hasRelatedWork W4376872470 @default.
• W3029053119 hasRelatedWork W71165227 @default.

• next